Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Past research has found that proton pump inhibitors and histamine H2 agonists are associated with lower levels of certain hep C drugs.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
These drugs are approved to treat all six major genotypes of hepatitis C.
This from a real-world analysis of people treated for hep C in the United States.
The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.
The subscription-based model is the first of its kind.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Researchers pooled data from numerous real-world cohorts from various nations.
People without hep C received kidney, liver or heart transplants from HCV-positive donors and then were treated for the virus.
The generally false presumption that they won’t adhere to the regimen is often used to deny coverage for hep C medications.
In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.
The high cost of hepatitis C treatment in the U.S. is about to see a major shift to lower prices of the major leading hepatitis C treatments
The drugs are set to come out in January 2019 with a list price of $24,000 for the most common dose for each.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.